Wolthers Ole D, Staberg Morten
Asthma and Allergy Clinic, Children's Clinic Randers, Dytmaersken 9, DK-8900 Randers, Denmark.
Recent Pat Inflamm Allergy Drug Discov. 2013 Jan 1;7(1):96-9.
Several patents of methods for diagnostic work-up of IgE-mediated disease have recently been acclaimed. The aim of the present study was to assess the diagnostic usefulness of the Multiple allergen simultaneous test-chemiluminescent assay (MAST CLA) as compared to the Phadia Immunocap (Phadia CAP) allergen-specific IgE test panel system. The design was a prospective, observational study in which MAST CLA and Phadia CAP test panels were assessed in 105 children aged 1 to 17 years (46 girls and 59 boys) with a suspected diagnosis of rhinoconjunctivitis, asthma, eczema or food allergy. The MAST CLA screening panel included 23 and 13, the Phadia CAP 10 inhalant and 6 food allergens. The MAST CLA screening panel found 353 sensitizations which were not detected by Phadia CAP, 93 (26.3%) of which were class 3 or 4 results. The sensitizations gave clinically useful information in 7 patients (6.6%). As compared to the Phadia CAP the MAST CLA screening test panel adds little to the diagnostic work-up of IgE mediated disease in children and adolescents.
最近，几种用于IgE介导疾病诊断检查的方法已获得专利。本研究的目的是评估多重变应原同步检测-化学发光法（MAST CLA）与法玛西亚免疫捕获法（Phadia CAP）变应原特异性IgE检测系统相比的诊断效用。该研究设计为一项前瞻性观察性研究，对105名年龄在1至17岁之间（46名女孩和59名男孩）疑似患有鼻结膜炎、哮喘、湿疹或食物过敏的儿童进行了MAST CLA和Phadia CAP检测。MAST CLA筛查组包括23种和13种变应原，Phadia CAP包括10种吸入性变应原和6种食物变应原。MAST CLA筛查组发现了353种Phadia CAP未检测到的致敏情况，其中93种（26.3%）为3级或4级结果。这些致敏情况为7名患者（6.6%）提供了临床有用信息。与Phadia CAP相比，MAST CLA筛查检测组对儿童和青少年IgE介导疾病的诊断检查贡献不大。
